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Purpose: The osseointegration around titanium mini-implants installed in macroporous biphasic calcium phosphate (MBCP) 
blocks was evaluated after incubation with recombinant human bone morphogenetic protein-2 (rhBMP-2) in an ectopic sub-
cutaneous rat model.
Methods: Mini-implants (ϕ1.8×12 mm) were installed in MBCP blocks (bMBCPs, 4×5×15 mm) loaded with rhBMP-2 at 0.1 
mg/mL, and then implanted for 8 weeks into subcutaneous pockets of male Sprague-Dawley rats (n=10). A histomorphomet-
ric analysis was performed, and the bone-to-implant contact (BIC) and bone density were evaluated.
Results: Significant osteoinductive activity was induced in the rhBMP-2/bMBCP group. The percentage of BIC was 41.23±
4.13% (mean±standard deviation), while bone density was 33.47±5.73%. In contrast, no bone formation was observed in the 
bMBCP only group.
Conclusions: This model represents a more standardized tool for analyzing osseointegration and bone healing along the 
implant surface and in bMBCPs that excludes various healing factors derived from selected animals and defect models.
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Research Article
INTRODUCTION 
Recombinant human bone morphogenetic protein-2 (rh-
BMP-2) is a member of the bone morphogenetic protein 
(BMP) family that is involved in de novo bone induction. In 
both preclinical and clinical settings, rhBMP-2 has been dem-
onstrated to induce bone formation in a variety of conditions 
including supra-alveolar periodontal defects [1], three-wall 
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intrabony periodontal defects [2], cleft palate defects [3], class 
III alveolar defects [4], calvarial defects [5,6], and ectopic sub-
cutaneous pockets [7]. The advent of dental implants, which 
are gradually replacing conventional prosthetic treatments, 
has recently expanded the application of rhBMP-2 to alveolar 
ridge augmentation [8-10] and sinus floor elevation [11], for 
which inadequate bone volume might adversely affect the 
long-term prognosis of dental implants [12]. 
Currently, various animal models exist for both implant os-
seointegration and rhBMP-2-enhanced bone regeneration 
including the ectopic rat model [13,14], supra-alveolar peri-im-
plant model [15-20], and mandible/tibia model [21,22]. Among 
these, the ectopic rat model is one of the most extreme in vivo 
osteoinduction models that completely exclude the osteo-
conductive factors from the surrounding native bone, there-
by enabling the evaluation of the effect of rhBMP-2 alone. 
This model is also considered to be one of the best models 
for evaluating the bone-forming potential of rhBMP-2 in 
combination with various implant surface treatments. Previ-
ous studies have already demonstrated that rhBMP-2 can in-
duce significant new bone regeneration around titanium 
implants transplanted into the subcutaneous pouches of im-
munocompromised mice [13,14]. However, such studies have 
ignored the crucial role of the scaffold, which allows cell in-
vasion for osteoinduction and retains rhBMP-2 at the im-
plantation site; tissue regeneration should always be consid-
ered in terms of basic factors such as cells, signals, and scaf-
folds [23]. Furthermore, the biomaterials used as a scaffold 
could duplicate the clinical characteristics of implants installed 
in alveolar bony ridges as well as in microenvironments in-
volving osteoconduction or osteoinduction.
Various materials have been utilized in combination as car-
rier materials for rhBMP-2 including hydroxyapatite, absorb-
able collagen sponge, β-tricalcium phosphate, and macropo-
rous biphasic calcium phosphate (MBCP). We previously 
evaluated the potential of MBCP block (bMBCP) for the ap-
plication of rhBMP-2 [24] and demonstrated significant new 
bone formation. In the present study, we evaluated bone 
healing and osseointegration around titanium mini-implants 
installed in bMBCPs treated with Escherichia coli-expressed 
rhBMP-2 to induce osseointegration in an ectopic subcuta-
neous rat model from a genetically homogeneous strain. 
This approach constituted a proof-of-concept study of osseo-
integration and ectopic bone formation in the rhBMP-2/bM-
BCP system that used a standardized experimental model to 
evaluate the sole effect of rhBMP-2 on both osseointegration 
and bone formation. To our knowledge, this is the first study 
to demonstrate ectopic osseointegration and bone formation 
using the rhBMP-2/bMBCP system.
MATERIALS AND METHODS
Expression of rhBMP-2 in E. coli
As previously described, rhBMP-2 was expressed in E. coli at 
the Research Institute of Cowellmedi (Busan, Korea) [25]. Brief-
ly, total RNA from human osteosarcoma cells was reverse-
transcribed with reverse transcriptase (Gibco BRL, Grand Is-
land, NY, USA). The cDNA encoding of the mature form of 
the BMP-2 protein was amplified via polymerase chain reac-
tion. The cDNA of human BMP-2 (hBMP-2) was then sub-
cloned into a pRSET(A) vector (Invitrogen, Paisley, UK) to 
produce the pRSET(A)/hBMP-2 expression vector, which was 
used to transform the E. coli BL21(DE3) strain. A high-cell 
density cultivation of E. coli was crushed twice in a French 
press and then centrifuged. The pellet was then resuspended 
at 25 mg wet weight/mL in a suspension buffer (20 mM Tris-
HCl [pH 8.5], 0.5 mM ethylenediaminetetraacetic acid [EDTA], 
and 2% v/v Triton X-100), and then centrifuged again. The 
inclusion bodies (pellets) were resuspended and incubated 
overnight. 
For the in vitro dimerization, the solubilized rhBMP-2 was 
incubated in a renaturation buffer (0.5 M guanidine-HCl, 50 
mM Tris-HCl [pH 8.5], 0.75 M N-cyclohexyl-2-aminoethane-
sulfonic acid, 1 M NaCl, 5 mM EDTA, and 3 mM total gluta-
thione). Purification of the active rhBMP-2 (dimer) was per-
formed with a heparin column (Heparin Sepharose 6 Fast 
Flow, GE Healthcare, Milwaukee, WI, USA). The active rh-
BMP-2 protein was eluted and separated using a stepped 
NaCl gradient (0.15, 0.3, and 0.5 M). Finally, this rhBMP-2 was 
reconstituted and diluted in a buffer to a concentration of 0.1 
mg/mL.
Kinetics of rhBMP-2 release from the bMBCP carrier
An experiment to determine the release kinetics of rhBMP-2 
in vitro was conducted using a slight modification of a previ-
ously described method [26]. Briefly, bMBCPs (n=5) loaded 
with 0.1 mL of rhBMP-2 solution were placed into 2 mL mi-
crocentrifuge tubes containing 1.0 mL of phosphate-buffered 
saline solution (pH 7.4) and 0.02% (w/v) sodium azide. The 
tubes were incubated at 37°C with continuous agitation. The 
supernatant medium was collected and completely replaced 
with a fresh buffer solution at the scheduled time points. The 
amount of rhBMP-2 in the supernatant was determined by a 
competitive indirect enzyme-linked immunosorbent assay 
(ELISA) for rhBMP-2 (Human BMP-2 R&D Systems, Minne-
apolis, MN, USA) according to the manufacturer’s protocol. 
The absorbance of the samples was read at 450 nm using an 
ELISA plate reader (Model 680, Bio-Rad Laboratories Inc., 
Hercules, CA, USA). The amount of rhBMP-2 was calculated 
with the aid of a calibration curve (Fig. 1).
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bMBCP construct with a mini-implant
Titanium-surfaced mini-implants (1.8 mm in diameter and 
12 mm long; Cheil Pharma and Instrument, Seoul, Korea) 
were placed into the bMBCPs (4×5×15 mm; Biomatlante, Vi-
gneux de Bretagne, France). The blocks had one longitudinal 
hole to allow for implant placement and three horizontal 
holes to facilitate bone healing (Fig. 2). The diameter of each 
horizontal hole was 2 mm, while that of the vertical hole was 
1.5 mm. Implants were installed manually along the vertical 
hole, with subsequent confirmation that they did not rotate 
after fixation. The bMBCP was treated overnight with either 
a phosphate buffer solution (control group) or rhBMP-2 solu-
tion at 0.1 mg/mL (test group) before transplantation.
Animals
Ten male Sprague-Dawley rats (body weight 250 to 300 g) 
were assigned to either the test or control group (n=5 animals 
per group). The animals were maintained in plastic cages in 
a room with a 12-hour day/night cycle, an ambient tempera-
ture of 21°C, and ad libitum access to water as well as a stan-
dard laboratory pellet diet. Animal selection, management, 
surgical protocol, and preparation followed routines approved 
by the Institutional Animal Care and Use Committee of Yon-
sei Medical Center in Seoul, Korea.
Surgical protocol
The animals were placed under general anesthesia using 
an intramuscular injection (5 mg/kg body weight) of ketamine 
hydrochloride (Ketalar, Yuhan, Seoul, Korea). The surgical site 
was shaved and scrubbed with iodine, and a vertical incision 
was then made in the skin of the back. After flap reflection, a 
subcutaneous pocket was prepared by blunt dissection, and a 
bMBCP with a titanium implant, treated or untreated with 
rhBMP-2, was implanted into the pocket. The skin was su-
tured for primary closure with 4-0 Vicryl sutures (Polyglactin 
910 braided absorbable suture, Ethicon, Johnson & Johnson, 
Edinburgh, UK). The animals were sacrificed after a healing 
period of 8 weeks, and samples were later obtained for histo-
logical analysis.
Histological analysis
After the bMBCP transplants were retrieved from the ani-
mals after necropsy, clinical photographs were taken (Fig. 3). 
Block samples were fixed in a 10% formalin solution, dehy-
drated in an ascending graded ethanol series (70%, 80%, 
90%, 95%, and 100%) and pure acetone, and then impreg-
nated and embedded in glycol methylmethacrylate. Polym-
erization was achieved by increasing the temperature from 
20°C to 80°C. Each resin block was cut into two sections (15 µm 
thickness) along the longitudinal axis of the biopsy sample 
using an internal circular diamond saw (Leitz, Wetzlar, Ger-
many) [25]. After staining with hematoxylin and eosin (H&E), 
all of the samples were examined with the aid of light and 
polarized-light microscopy (BX50, Olympus Co., Tokyo, Japan), 
as well as scanning electron microscopy (SEM; S-4300, Hita-
chi, Tokyo, Japan). The SEM observations were performed af-
ter the sections were polished and sputtered with gold palla-
Figure 1. Kinetics of recombinant human bone morphogenetic pro-
tein-2 (rhBMP-2) release from macroporous biphasic calcium phos-
phate block observed in vitro. Sustained release of rhBMP-2 was ob-
served for up to 2 weeks. 
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Figure 2. Clinical photograph of a macroporous biphasic calcium 
phosphate block (bMBCP) and titanium mini-implant installation. 
One vertical hole and three horizontal holes are present in the bM-
BCP. The titanium mini-implant was installed manually. 
A B C
Figure 3. Clinical photograph of a macroporous biphasic calcium 
phosphate block (bMBCP) retrieved after necropsy. (A) High-density 
connective tissue formation was observed with infiltration of mi-
crovessels in the test group (recombinant human bone morphoge-
netic protein-2/bMBCP). (B) Loose connective tissue, which was 
easily wiped off, dominantly formed over the bMBCP in the control 
group (phosphate buffer solution/bMBCP).
Test group Control group
A B
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dium, using secondary and back-scattered electrons at 15 kV 
(Leo 1450VP, Zeiss, Germany). The most central section from 
each block was selected to compare the findings between the 
groups. New bone formation and osseointegration in H&E-
stained histological slides were analyzed quantitatively using 
an image analysis system (Image-Pro Plus; Media Cybernet-
ics, Silver Spring, MD, USA). The following parameters were 
measured: 1) Bone-to-implant contact (BIC): The length of 
osseointegration that was along the thread profile and in di-
rect contact with the newly formed bone was calculated for 
both sides of the implant on each of the two central sections 
obtained from each implant; 2) Bone density within the im-
plant threads: The area of the newly formed bone within the 
implant threads was measured. The value of each was ex-
pressed as a percentage.
RESULTS
The rhBMP-2 release kinetics of bMBCP were evaluated in 
vitro (Fig. 1). Approximately 80% of the loaded rhBMP-2 was 
released during the first 4 days. However, rhBMP-2 was con-
tinuously released for up to 2 weeks. Clinical healing was un-
eventful. In the test group, the horizontal holes became com-
pletely filled with hard collagenous tissues that were firmly 
attached to the block (Fig. 3A). Small diameter blood vessels 
were integrated within the dense fibrous tissue. The collage-
nous tissue could not be easily rubbed off from the bMBCP 
surface, suggesting highly increased tissue integration. Con-
versely, loosely formed connective tissue was formed along 
the bMBCP block of the control group, which was easily 
washed off (Fig. 3B).
Histomorphometric analysis using H&E staining
The general pattern of bone formation was favorable in the 
test group, which was in line with the results from previous 
studies [24,27,28]. Newly formed bone stained with H&E ex-
hibited a high-density, predominantly lamellated bone pat-
tern along the implant surface and within the micropores of 
the bMBCP. This pattern was different from the control group, 
in which no mineralized tissue had formed. The distribution 
of the newly formed bone was equally observed along the 
implant and bMBCP surfaces, while the bridging pattern be-
tween the implant and bMBCP surfaces was clearly evident. 
The newly formed bone did not appear to be homogeneous 
and exhibited cement lines separating areas of bone that had 
been deposited at different times. The new bone appeared to 
be well mineralized and had numerous lacunae. Numerous 
osteocytes were observed, as well as a few osteoblasts that 
were aligned along the surface of the newly formed bone.
The results of the histomorphometric analysis are shown 
in Table 1. The percentage of direct BIC was 41.23±4.13% 
(mean±standard deviation) in the test group (n=5), while the 
control group exhibited no bone formation along the titani-
um mini-implants (n=5). The bone density in the test group 
was 33.47±5.73%.
Light microscopy, polarized-light microscopy, and SEM 
analysis 
Polarized-light microscopy was used to evaluate the pat-
terns of lamellation in the newly formed bone, which is con-
sidered to be an important hallmark of bone maturation. In 
the treated group, groups of mineralized collagen fibers with 
numerous osteocytes were clearly observed under polarized 
light (Fig. 4C), while there appeared to be new bone forma-
tion in direct contact with the bMBCP and implant surfaces. 
Conversely, no mineralized tissue was found in the control 
group (Fig. 4F).
The back-scattered SEM images confirmed that the area of 
newly formed bone was significantly larger in the rhBMP-2-
treated group than in the untreated control group 8 weeks 
after transplantation (Fig. 5). Newly formed bone was gener-
ally observed within the bMBCP pores and along the implant 
surface, appearing as light-gray areas. However, no mineral-
ized tissue was observed in the sections from the control 
group. Collectively, mineralized bony tissue on the implant 
and bMBCP surfaces (including osteocytes, a Haversian sys-
tem, and cement lines) was observed exclusively in the test 
group both during polarized light microscopy and in back-
scattered SEM images.
DISCUSSION
To the best of our knowledge, this is the first report of an 
ectopic osseointegration analysis model based on titanium 
mini-implants and the rhBMP-2/bMBCP system, which 
closely simulated clinical parameters. We also evaluated the 
true osseointegration potential of rhBMP-2 by excluding 
other contributing factors. This study confirmed the feasibil-
ity of this evaluation model and the new bone formation po-
tential of rhBMP-2. The results suggest that candidates for 
Table 1. Measured bone-to-implant contact (BIC) and bone density 
of the newly formed bone. 
BIC (%) Bone density (%)
Test group (rhBMP-2/bMBCP) 41.23±4.13 33.47±5.73
Control group (phosphate buffer solution/
bMBCP)
0 0
Values are presented as mean±standard deviation.
rhBM-2: recombinant human bone morphogenetic protein-2, bMBCP: macroporous 
biphasic calcium phosphate block. 
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bone induction and techniques for new bone formation and 
osseointegration can be analyzed without experimental er-
rors using this model.
The present study achieved clinically relevant amounts of 
BIC and an adequate density of newly formed bone within a 
relatively short period of time. This finding is in agreement 
with previous results, suggesting that the mechanism of new 
bone formation involves initiation of the osteoinduction cas-
cade by MBCP at the local site and support for osteoinduc-
tive capacity by rhBMP-2 [24,27,29]. The potential of BMPs to 
induce new bone formation is crucially dependent on the 
characteristics of the carrier [30,31]. Moreover, it has been re-
ported that the surface microstructure plays an important 
role in the osteoinductive effect of biomaterials [32]; the mi-
crostructure may allow biological apatite to precipitate and 
induce cells to attach to the surfaces of biomaterials. In par-
ticular, micropores with diameters smaller than 5 µm might 
serve as nucleation sites for biological apatite precipitation 
because they can facilitate ionic exchange with body fluids 
[33]. Additionally, micropores at the MBCP surface may favor 
the adsorption and entrapment of rhBMP-2, which has a 
high affinity for calcium phosphates [34]. As such, this micro-
environment can enhance the adhesion and differentiation 
of progenitor cells into osteoblasts. Our results demonstrate 
that bMBCP can potentially mimic the clinical healing envi-
ronment of an implant installed in the alveolar ridge.
In this study, newly formed bone was generally observed 
on implant surfaces and within the vertical and horizontal 
holes. A possible mechanism underlying this phenomenon 
appears to be related to the specific microenvironment of 
bMBCP. It has been reported that microparticles or ionic 
molecules are released from MBCP during the initial healing 
period [35] and that the released microparticles may induce 
the local release of inflammatory cytokines. This release of 
cytokines stimulates circulating stem cells to repopulate on 
the MBCP surface and differentiate into osteoblasts, thereby 
producing bone tissue. In our study, the sustained release of 
rhBMP-2 in the bMBCP for a relevantly long period may 
have induced these osteoblastic differentiation cascades. 
Even though bone formation and osseointegration were 
evenly distributed, more bone formation was observed in the 
vertical hole of the implant apex. We postulated that the os-
Figure 4. Histological overview of the retrieved titanium mini-im-
plants and recombinant human bone morphogenetic protein-2/
macroporous biphasic calcium phosphate blocks (rhBMP-2/bMB-
CPs) or phosphate buffer solution/bMBCPs (H&E staining). (A, B) 
The rhBMP-2-treated test group presenting significant new bone 
formation along the implant surface and within the bMBCP (A, ×40; 
B, ×200). (C) The newly formed bone exhibited a lamellated pattern 
under polarized-light microscopy, suggesting the occurrence of 
waves of differentiated bone formation over time (×200). (D, E) The 
untreated control group demonstrated no mineralized tissue for-
mation along the implant surface or within the bMBCP (D, ×40; E, 
×200). (F) No mineralized tissue was observed under polarized-light 
microscopy in the control tissue (×200). Ti: titanium mini-implant, 
M: bMBCP, NB: new bone.
Figure 5. (A) Scanning electron microscopy (SEM) images of the test 
group (recombinant human bone morphogenetic protein-2/macro-
porous biphasic calcium phosphate blocks [bMBCPs]) 8 weeks after 
subcutaneous implantation in rats (×50). A higher magnification of 
the boxed area is shown in B. New bone formation is evident along 
the implant surface. The bMBCP is revealed as dark-gray areas, 
while MBCP and the titanium mini-implant appear as light-gray 
and white, respectively. (B) A higher magnification view of the boxed 
area clearly shows newly formed bone tissue (×100). The yellow ar-
rowheads indicate the obvious formation of NB. (C) The SEM imag-
es of the control group (phosphate buffer solution/bMBCP) (×50). 
(D) Polarized-light microscopy showing the absence of mineralized 
tissue (×100). Ti: titanium mini-implant, M: bMBCP, NB: new bone.
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teoinductive properties were favorably enhanced by the spe-
cific microenvironment in this area, although additional 
studies are required to fully address this phenomenon. 
Previous studies have demonstrated that carrier type can 
influence the effectiveness of rhBMP-2-induced bone for-
mation, with several types of carrier systems having been 
suggested for the clinical use of rhBMPs [7,27,32,33,36,37]. 
MBCP is reportedly one of the most effective carrier systems 
for rhBMPs [29] and is composed of hydroxyapatite and tri-
calcium phosphate at a ratio of 60:40. MBCP also exhibits an 
excellent capacity for bone conduction and induction [34,35], 
which is accelerated when incorporated with rhBMP-2 [38,39]. 
Although we did not observe any ectopic bone formation in 
the control group in this study, other reports have described 
MBCP-induced ectopic new bone formation [34,35]. Particu-
larly, excellent bone induction was observed when a pow-
dered type of MBCP was used as an rhBMP-2 carrier, which 
shows its potential for future clinical application.
Research into the effects of rhBMPs on implant osseointe-
gration has focused mainly on the alveolar bone defect mod-
el in canines. However, an orthotopic model in canines is 
difficult to standardize because of the individuality of the 
animals as well as the different healing patterns and varia-
tions in both bone quantity and quality, which may be associ-
ated with different healing vectors. Furthermore, most defect 
morphologies cannot exclude the contribution of each pa-
tient’s innate healing potential. Therefore, it has been difficult 
to analyze the isolated induction capacity of rhBMP-2 on os-
seointegration and bone regeneration. The results of the 
present study, which involved a genetically identical rat strain, 
revealed that favorable ectopic new bone formation and os-
seointegration were possible using an rhBMP-2/bMBCP sys-
tem. In addition, minimal bone formation was observed in 
the control group, indicating that this evaluation model was 
very standardized and reliable as a result of the exclusion of 
innate bone forming potential; this suggests that our stan-
dardized model was a good candidate for the analysis of or-
thotopic implant osseointegration. 
Within the limitations of this study, the histology results, 
the polarized-light microscopy, and SEM analyses all dem-
onstrated that impregnation of rhBMP-2 into a bMBCP sig-
nificantly induced osteoinductive activity and enhanced os-
seointegration in subcutaneous rat tissues at 8 weeks. The ti-
tanium mini-implant and rhBMP-2/bMBCP system can be 
used to evaluate isolated healing characteristics of bone re-
generation and osseointegration resulting from rhBMP-2, 
while excluding the innate healing factors from the host. We 
postulate that this specific model could be widely used in the 
process of developing new implant surfaces. 
In conclusion, this model represents a more standardized 
tool for analyzing osseointegration and bone healing along 
the implant surface and bMBCP that excludes various heal-
ing factors derived from selected animals and defect models.
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